Table II.
Clinicopathological characteristic of the patients with high-grade serous advanced ovarian cancer (n = 135)
| Parameter | N | % |
|---|---|---|
| FIGO stage: | ||
| IIIA | 7 | 5.1 |
| IIIB | 22 | 16.2 |
| IIIC | 81 | 60.3 |
| IVA | 9 | 6.6 |
| IVB | 16 | 11.8 |
| Lymph nodes: | ||
| N0 | 14 | 10.3 |
| N1 | 118 | 87.4 |
| Not determined | 3 | 2.3 |
| Volume of ascites: | ||
| No ascites | 14 | 10.4 |
| Ascites ≤ 500 ml | 67 | 49.6 |
| Ascites > 500 ml | 54 | 40.0 |
| ECOG PS: | ||
| 0 | 107 | 79.2 |
| 1–2 | 28 | 20.8 |
| Tumor residuals: | ||
| 0 | 90 | 66.6 |
| 1–10 mm | 39 | 28.8 |
| > 10 mm | 6 | 4.6 |
FIGO – International Federation of Gynecology and Obstetrics, ECOG PS – Eastern Cooperative Oncology Group performance.